TD Cowen downgraded Kronos Bio (KRON) to Hold from Buy without a price target after the company announced the decision to halt clinical development of its lead candidate istisociclib due to an unfavorable safety-benefit profile. The company is currently exploring a range of strategic alternatives, including potential transactions involving its two proprietary p300 KATi’s under preclinical development, KB-9558 and KB-9798, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRON:
- Kronos Bio downgraded to Neutral from Overweight at Piper Sandler
- Kronos Bio reports Q3 EPS (23c), consensus (28c)
- Kronos Bio files $250M mixed securities shelf
- Kronos Bio to present data at ASH annual meeting on p300 KAT inhibitor program
- KRON Earnings Report this Week: Is It a Buy, Ahead of Earnings?